Your browser doesn't support javascript.
loading
Managing thyrotoxicosis in the acute medical setting.
Napier, C.
Affiliation
  • Napier C; MBBS MRCP (UK), Endocrine Unit, Royal Victoria Infirmary, Queen Victoria Road, Newcastle Upon Tyne, NE1 4LP UK.
Acute Med ; 17(1): 44-48, 2018.
Article de En | MEDLINE | ID: mdl-29589605
ABSTRACT
Thyrotoxicosis is common and can present in numerous ways with patients exhibiting a myriad of symptoms and signs. It affects around 1 in 2000 people annually in Europe1. The thyroid gland produces two thyroid hormones - thyroxine (T4) and triiodothyronine (T3). Thyroxine is inactive and is converted by the tissues and organs that need it into tri-iodothyronine. In health, the production of these thyroid hormones is tightly regulated by the secretion of thyroid stimulating hormone (TSH; thyrotropin) from the pituitary gland. The term 'thyrotoxicosis' refers to the clinical manifestations of hyperthyroidism.
Sujet(s)
Recherche sur Google
Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thyréotoxicose Type d'étude: Diagnostic_studies / Etiology_studies Limites: Humans Langue: En Journal: Acute Med Année: 2018 Type de document: Article
Recherche sur Google
Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thyréotoxicose Type d'étude: Diagnostic_studies / Etiology_studies Limites: Humans Langue: En Journal: Acute Med Année: 2018 Type de document: Article
...